简体
  • 简体中文
  • 繁体中文
×

热门资讯> 正文

Citius Oncology宣布注册直接发行1800万美元

2025-12-09 21:49

  • Citius Oncology (CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals (CTXR), announced on Tuesday that it has entered into a definitive agreement with a single healthcare-focused investor for the purchase and sale of 1.28 million shares of its common stock at a purchase price of $1.09 per share in a registered direct offering.
  • In addition, the company has agreed to issue to the investor unregistered warrants to purchase up to 1.28 million shares of common stock at an exercise price of $1.09 per share, which will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock upon exercise of the warrants and will expire five years from the date of stockholder approval.
  • Concurrently with the registered direct offering, in a private placement priced at-the-market under Nasdaq rules, the company entered into a definitive agreement with the investor for the purchase and sale of 15.23 million shares of common stock and warrants to purchase up to 15.23 million shares of the company's common stock at a purchase price of $1.09 per share and accompanying warrant.
  • The warrants to be issued in the private placement have an exercise price of $1.09 per share, will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock upon exercise of the warrants and will expire five years from the date of stockholder approval.
  • The closing of the offerings is expected to occur on or about December 10, 2025.
  • The gross proceeds from the offerings, before deducting the placement agent's fees and other offering expenses payable by the company, are expected to be approximately $18 million. 
  • The company intends to use the net proceeds from the offerings to support the commercial launch of LYMPHIR and for working capital and general corporate purposes.
  • CTXR -7.14% premarket to $1.04.
  • Source: Press Release

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
问答大全
（工作日09：30 - 次日05：30）
客户端：
关注我们：
  • 微信公众号二维码

© 2025 深圳市时代华盛网络科技有限公司版权所有 粤ICP备16068286号